Cargando…

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives

Achieving a pathologic complete response after neoadjuvant treatment is associated with improved prognosis in breast cancer. The CREATE-X trial demonstrated a significant survival improvement with capecitabine in patients with residual invasive disease after neoadjuvant chemotherapy, and the KATHERI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caparica, Rafael, Lambertini, Matteo, Pondé, Noam, Fumagalli, Debora, de Azambuja, Evandro, Piccart, Martine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393951/ https://www.ncbi.nlm.nih.gov/pubmed/30833989 http://dx.doi.org/10.1177/1758835919827714

Ejemplares similares

How I treat metastatic triple-negative breast cancer
por: Caparica, Rafael, et al.
Publicado: (2019)

Twenty years of anti-HER2 therapy-associated cardiotoxicity
por: Pondé, Noam F, et al.
Publicado: (2016)

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis
por: Brandão, Mariana, et al.
Publicado: (2020)

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial
por: Lambertini, Matteo, et al.
Publicado: (2020)

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
por: Snoj, Natasa, et al.
Publicado: (2009)

Cancer drugs, survival and ethics: a critical look from the inside
por: Piccart, Martine, et al.
Publicado: (2017)

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?
por: Agostinetto, Elisa, et al.
Publicado: (2020)

CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis
por: Agostinetto, E., et al.
Publicado: (2021)

Phosphoethanolamine and the danger of unproven drugs
por: Pondé, Noam, et al.
Publicado: (2016)

Threat posed by unproven drugs in medical oncology
por: Pondé, Noam, et al.
Publicado: (2016)

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
por: Pondé, Noam, et al.
Publicado: (2019)

Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2023)

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
por: Lambertini, Matteo, et al.
Publicado: (2018)

Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?
por: Poggio, Francesca, et al.
Publicado: (2018)

Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy
por: Lambertini, Matteo, et al.
Publicado: (2022)

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2022)

Oncofertility counselling in premenopausal women with HER2-positive breast cancer
por: Lambertini, Matteo, et al.
Publicado: (2019)

Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer
por: Agostinetto, Elisa, et al.
Publicado: (2022)

Neoadjuvant treatment: the future of patients with breast cancer
por: Reyal, F, et al.
Publicado: (2018)

Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA
por: Ades, Felipe, et al.
Publicado: (2017)

Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis
por: Azim, Hatem A., et al.
Publicado: (2013)

Correction: Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis
por: Azim, Hatem A., et al.
Publicado: (2013)

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
por: Kourie, Hampig Raphael, et al.
Publicado: (2017)

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
por: Eiger, Daniel, et al.
Publicado: (2020)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021)

Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Neoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectives
por: Imperatori, Marco, et al.
Publicado: (2016)

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
por: Rossari, José R., et al.
Publicado: (2012)

State of the art in neoadjuvant therapy of breast cancer
por: Minckwitz, Gunter von, et al.
Publicado: (2013)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2015)

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer
por: Maurer, Christian, et al.
Publicado: (2018)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
por: Mina, Roberto, et al.
Publicado: (2020)

Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials
por: Eiger, Daniel, et al.
Publicado: (2020)

Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma
por: Okubo, Satoshi, et al.
Publicado: (2019)

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
por: Brandão, M, et al.
Publicado: (2019)

Targeted therapies in breast cancer: are heart and vessels also being targeted?
por: Criscitiello, Carmen, et al.
Publicado: (2012)

Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
por: Lerebours, Florence, et al.
Publicado: (2021)

Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25
por: Pinto, Ana Catarina, et al.
Publicado: (2014)

Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis
por: Caparica, Rafael, et al.
Publicado: (2021)

Monogenic Autoinflammatory Diseases: State of the Art and Future Perspectives
por: Di Donato, Giulia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gkfmaor9lhld6i0q518r05ashe